中国癌症杂志 ›› 2018, Vol. 28 ›› Issue (7): 481-486.doi: 10.19401/j.cnki.1007-3639.2018.07.001

• 专家述评与论著 • 上一篇    下一篇

核医学分子影像在分化型甲状腺癌中的应用现状与进展

李 慧1,2 综述,林岩松1,2 审校   

  1. 1. 中国医学科学院北京协和医学院北京协和医院核医学科,北京 100730 ;
    2. 核医学分子靶向诊疗北京市重点实验室,北京 100730
  • 出版日期:2018-07-30 发布日期:2018-08-10
  • 通信作者: 林岩松 E-mail: linyansong1968@163.com
  • 基金资助:
    国家自然科学基金(81571714,81771875);北京协和医学院研究生创新基金(1002-02-08)。

Molecular imaging of nuclear medicine in differentiated thyroid cancer: current status and future direction

LI Hui1,2, LIN Yansong1,2   

  1. 1. Department of Nuclear Medicine, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China; 2. Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Beijing 100730, China
  • Published:2018-07-30 Online:2018-08-10
  • Contact: LIN Yansong E-mail: linyansong1968@163.com

摘要: 分化型甲状腺癌因其发病率逐年升高而引人关注,核医学诊疗是其诊疗过程中重要的一环。随着新型示踪剂的发展,核医学分子影像检查对于在体显示甲状腺癌特定的分子特征及表达水平有重要价值,并可实现基于在体分子特征评估指导下的精准靶向治疗。现就核医学分子影像在评估分化型甲状腺癌分化表型特征和非分化表型特征两方面的应用与进展进行综述。

关键词: 分化型甲状腺癌, 核医学分子影像, 分化表型特征, 非分化表性特征

Abstract: With the increasing of incidence, differentiated thyroid cancer (DTC) has become a global concern.Nuclear medicine plays an important role in the diagnosis and treatment of DTC. With the development of new tracers, molecular imaging of nuclear medicine has shown great value in demonstrating the molecular characteristics and its expression level of DTC, and can be used to guide the precise target therapy based on molecular nuclear imaging in vivo. Here we present this review on the current status and future direction of the application of molecular nuclear imaging in evaluating the differentiated and non-differentiated phenotype characteristics in DTC.

Key words: Differentiated thyroid cancer, Molecular imaging of nuclear medicine, Differentiated phenotype characteristics, Non-differentiated phenotype characteristics